Marine algae-derived oligosaccharide via protein crotonylation of key targeting for management of type 2 diabetes mellitus in the elderly.

Global aging is a tendency of the world, as is the increasing prevalence of diabetes, and the two are closely linked. In our early research, Enteromorpha prolifera oligosaccharide (EPO) possesses the excellent ability of anti-oxidative, anti-inflammatory, and anti-diabetic. We aim to further explore the deeper mechanism of how EPO delays aging and regulates glycometabolism. EPO effectively impacts crotonylation procession to enhance glucose metabolism and reduce cell senescence in aging diabetic rats. Crotonylation modification of XPO1 influences the expression of critical genes, including p53, CDK1, and CCNB1, which affect cell cycle regulation and aging. Additionally, EPO improves glucose metabolism by inhibiting the crotonylation modification of HSPA8-K126 and activating the AKT pathway. EPO promotes crotonylation of histones in intestinal cells, influencing the aging process by increasing the butyric acid-producing bacteria Ruminococcaceae. The observed enhancement in pyrimidine metabolism underscores EPO's potential role in regulating intestinal health, presenting a promising avenue for delaying aging. In summary, our findings affirm EPO as a naturally bioactive ingredient with significant potential for anti-aging and antidiabetic interventions.

The therapeutic potential for senescence-associated diabetes of green alga Enteromorpha prolifera polysaccharide.

DEAE-52 and Sephadex G-100 columns were used to isolate Enteromorpha prolifera polysaccharide (EPP), which contains α-L-Rhap-(1 â†’ 4)-α-L-Arap-(1 â†’ 2)-α-L-Rhap-(1 â†’ 3)-ß-D-Galp-(1 â†’ structural fragment, along with α-L-Rhap-(1 â†’ and →2)-α-L-Rhap-(1 â†’ 3)-ß-D-GlcpA-(1 â†’ side bonds that connect to →3,6)-ß-D-Galp-(1→. The anti-ageing and hypoglycemic activities of EPP were assessed using an ageing diabetic mice model, and the revealed that EPP could improve glucose metabolism-associated parameters and inhibit the expression of ageing associated genes, including p16INK4a, p38 MAPK, NOX-1, VEGF, and AGER, thus preventing liver damage. Moreover, gut microbiota profiling revealed that EPP significantly increased the abundances of o_Lactobacillaceae, c_Bacilli, f_Lactobacillaceae, g_Lactobacillus, and p_Firmicutes, showing that EPP has a probiotic effect on enhancing the beneficial microbiota in ageing diabetic mice. In summary, EPP might serve as a potential bioactive compound to alleviate hyperglycaemia and ageing in diabetic in mice and further clinical studies are required to verify these effects.

A 3D co-culture intestinal organoid system for exploring glucose metabolism.

Many treatments have been used for glucose metabolism diseases such as type 2 diabetes, and all of those treatments have several advantages as well as limitations. This review introduces a 3D co-culture intestinal organoid system developed from stem cells, which has the special function of simulating human tissues. Recent studies have revealed that the gut is an important site for exploring the interactions among glucose metabolism, gut microbial metabolism, and gut microbiota. Therefore, 3D intestinal organoid systems can be used to imitate the congenital errors of human gut development, drug screening, food transportation and toxicity analysis. The intestinal organoid system construction methods and their progress as compared with traditional 2D culture methods have also been summarised in the manuscript. This paper discusses the research progress in terms of intestinal organoids applicable to glucose metabolism and provides new ideas for developing anti-diabetic drugs with high efficiency and low toxicity.